OPR - Delayed Quote • USD NUVL Jul 2024 90.000 call (NUVL240719C00090000) Follow 1.1500 0.0000 (0.00%) As of April 15 at 9:30 AM EDT. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for NUVL240719C00090000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: NUVL Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 Chief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL) ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors Chief Legal Officer Deborah Miller Sells 22,000 Shares of Nuvalent Inc (NUVL) Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL) Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth Director Emily Conley Sells 13,333 Shares of Nuvalent Inc (NUVL) Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 Nuvalent Inc (NUVL) Reports Full Year and Q4 2023 Financial Results with Strong Cash Position ... Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 13 Best Short Squeeze Stocks To Buy Now
